



ASX RELEASE
4 February 2015

**Entitlement Offer cleansing notice under section 708AA(2)(f) Corporations Act -
Tissue Therapies Limited (ASX Code: TIS)**

On 4 February 2015, Tissue Therapies Limited (**Tissue Therapies**) announced a A\$3.7 million equity raising through a 1 for 15 non-renounceable entitlement offer of fully paid ordinary shares in Tissue Therapies (**New Shares**) (**Entitlement Offer**).

The offer has been fully underwritten by Morgans Corporate Limited and Baillieu Holst Ltd (**Underwriters**).

Tissue Therapies will offer the New Shares for issue without disclosure to investors under section 708AA(2)(f) *Corporations Act 2001* (**Corporations Act**) as notionally modified by ASIC Class Order 08/35 (**CO 08/35**).

For the purposes of section 708AA(7) Corporations Act, Tissue Therapies advises:

- (a) the New Shares will be offered for issue without disclosure under Part 6D.2 Corporations Act as notionally modified by CO 08/35;
- (b) this notice is given under section 708AA(2)(f) Corporations Act as notionally modified by CO 08/35;
- (c) as at the date of this notice, Tissue Therapies has complied with:
 - (i) the provisions of Chapter 2M Corporations Act as they apply to Tissue Therapies; and
 - (ii) section 674 Corporations Act,
- (d) as at the date of this Notice, there is no excluded information of the type referred to in section 708AA(8) and 708AA(9) Corporations Act as notionally modified by CO 08/35; and
- (e) the potential effect that the Entitlement Offer will have on the control of Tissue Therapies, and the consequences of that effect, is that, in the likely event that some shareholders do not take up their full entitlement, those shareholder's percentage holdings in Tissue Therapies will be diluted by those other shareholders who take up some, all or more than their entitlement (i.e. by subscribing for shortfall shares).

The Underwriters will either place the shortfall to sub-underwriters or take up the shortfall themselves. Having regard to the number of shares to be issued under the Entitlement Offer, even if a substantial shortfall eventuated, the Underwriters or sub-underwriters would not be in a position to exercise any substantive control in Tissue Therapies.

Further details regarding the Entitlement Offer are set out in the Information Booklet.

Signed for and on behalf of Tissue Therapies.



Steven Mercer
Managing Director
Tissue Therapies Limited

For further information contact:

If you have any queries, please call 1800 063 366 (inside Australia) or +61 1800 063 366 (outside Australia) between 8.30am and 5.00pm (AEDT) Monday to Friday during the offer period or, alternatively, consult your professional adviser.

What is VitroGro[®] ECM

- VitroGro[®] ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro[®] ECM replaces the degraded matrix of a hard to heal wound. VitroGro[®] ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration ^[1].
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process ^[1,2,3,4]. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds ^[1]. VitroGro[®] ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modelling indicates that VitroGro[®] ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD . Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro[®] ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: www.tissuetherapies.com